FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176912797> ?p ?o ?g. }

• W3176912797 endingPage "300.e8" @default.
• W3176912797 startingPage "300.e1" @default.
• W3176912797 abstract "Hepatitis B virus infection is an important public health problem. We analysed the cost-effectiveness of the first-line therapies, including nucleotide analogues (namely tenofovir alafenamide fumarate (TAF), tenofovir disoproxil fumarate (TDF) and entecavir) and pegylated interferon (Peg-IFN) for patients with chronic hepatitis B (CHB) in China.A Markov model describing CHB disease progression was constructed to compare the cost-effectiveness of the first-line therapies, considering both satisfactory (HBeAg seroconversion) and optimal (HBsAg seroclearance) treatment goals. We examined the main outcomes, including cumulative lifetime cost per patient, incremental quality-adjusted life years (QALYs), incremental cost-effectiveness ratio and net monetary benefit. Uncertainty analysis was conducted to identify key influential parameters.Compared with the baseline strategy, Peg-IFN had the highest QALY gain for HBeAg-positive (HBeAg+) CHB patients achieving a satisfactory goal and an optimal goal (3.19 and 6.32 respectively), and TDF was the most cost-effective therapy for HBeAg-negative CHB patients ($1418/QALY) achieving a satisfactory goal. Among nucleotide analogues, TAF was the most-effective strategy and had higher acceptability to achieve an optimal goal in the Eastern region of China (under 1 x GDP per capita threshold).Among nucleotide analogues, TDF was the most cost-effective treatment in China for CHB patients to achieve satisfactory and optimal treatment goals, whereas TAF was cost-effective and more effective in the wealthier region. Peg-IFN was most cost-effective among HBeAg+ CHB patients to achieve both goals, with better clinical outcomes. Our findings also indicate the importance of regular monitoring during and after CHB treatment, and could inform treatment strategies in China and other countries." @default.
• W3176912797 created "2021-07-05" @default.
• W3176912797 creator A5001890971 @default.
• W3176912797 creator A5026431465 @default.
• W3176912797 creator A5033742839 @default.
• W3176912797 creator A5036569805 @default.
• W3176912797 creator A5068301817 @default.
• W3176912797 creator A5068660339 @default.
• W3176912797 creator A5074628828 @default.
• W3176912797 date "2022-02-01" @default.
• W3176912797 modified "2023-10-14" @default.
• W3176912797 title "Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China" @default.
• W3176912797 cites W1821077834 @default.
• W3176912797 cites W1867498798 @default.
• W3176912797 cites W1983189434 @default.
• W3176912797 cites W2004078003 @default.
• W3176912797 cites W2008517556 @default.
• W3176912797 cites W2009554180 @default.
• W3176912797 cites W2011736290 @default.
• W3176912797 cites W2024267100 @default.
• W3176912797 cites W2036627386 @default.
• W3176912797 cites W2040280766 @default.
• W3176912797 cites W2058600986 @default.
• W3176912797 cites W2106415541 @default.
• W3176912797 cites W2114785561 @default.
• W3176912797 cites W2133104890 @default.
• W3176912797 cites W2146353434 @default.
• W3176912797 cites W2155246976 @default.
• W3176912797 cites W2491309586 @default.
• W3176912797 cites W2588244195 @default.
• W3176912797 cites W2789369329 @default.
• W3176912797 cites W2791839818 @default.
• W3176912797 cites W2893215204 @default.
• W3176912797 cites W2903260180 @default.
• W3176912797 cites W2976188712 @default.
• W3176912797 doi "https://doi.org/10.1016/j.cmi.2021.06.024" @default.
• W3176912797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34197929" @default.
• W3176912797 hasPublicationYear "2022" @default.
• W3176912797 type Work @default.
• W3176912797 sameAs 3176912797 @default.
• W3176912797 citedByCount "2" @default.
• W3176912797 countsByYear W31769127972023 @default.
• W3176912797 crossrefType "journal-article" @default.
• W3176912797 hasAuthorship W3176912797A5001890971 @default.
• W3176912797 hasAuthorship W3176912797A5026431465 @default.
• W3176912797 hasAuthorship W3176912797A5033742839 @default.
• W3176912797 hasAuthorship W3176912797A5036569805 @default.
• W3176912797 hasAuthorship W3176912797A5068301817 @default.
• W3176912797 hasAuthorship W3176912797A5068660339 @default.
• W3176912797 hasAuthorship W3176912797A5074628828 @default.
• W3176912797 hasConcept C112930515 @default.
• W3176912797 hasConcept C126322002 @default.
• W3176912797 hasConcept C203014093 @default.
• W3176912797 hasConcept C2522874641 @default.
• W3176912797 hasConcept C2775940106 @default.
• W3176912797 hasConcept C2776175608 @default.
• W3176912797 hasConcept C2776461080 @default.
• W3176912797 hasConcept C2777410769 @default.
• W3176912797 hasConcept C2777869810 @default.
• W3176912797 hasConcept C2780040827 @default.
• W3176912797 hasConcept C2780593183 @default.
• W3176912797 hasConcept C3019080777 @default.
• W3176912797 hasConcept C3020491458 @default.
• W3176912797 hasConcept C515549039 @default.
• W3176912797 hasConcept C71924100 @default.
• W3176912797 hasConceptScore W3176912797C112930515 @default.
• W3176912797 hasConceptScore W3176912797C126322002 @default.
• W3176912797 hasConceptScore W3176912797C203014093 @default.
• W3176912797 hasConceptScore W3176912797C2522874641 @default.
• W3176912797 hasConceptScore W3176912797C2775940106 @default.
• W3176912797 hasConceptScore W3176912797C2776175608 @default.
• W3176912797 hasConceptScore W3176912797C2776461080 @default.
• W3176912797 hasConceptScore W3176912797C2777410769 @default.
• W3176912797 hasConceptScore W3176912797C2777869810 @default.
• W3176912797 hasConceptScore W3176912797C2780040827 @default.
• W3176912797 hasConceptScore W3176912797C2780593183 @default.
• W3176912797 hasConceptScore W3176912797C3019080777 @default.
• W3176912797 hasConceptScore W3176912797C3020491458 @default.
• W3176912797 hasConceptScore W3176912797C515549039 @default.
• W3176912797 hasConceptScore W3176912797C71924100 @default.
• W3176912797 hasIssue "2" @default.
• W3176912797 hasLocation W31769127971 @default.
• W3176912797 hasLocation W31769127972 @default.
• W3176912797 hasOpenAccess W3176912797 @default.
• W3176912797 hasPrimaryLocation W31769127971 @default.
• W3176912797 hasRelatedWork W161314224 @default.
• W3176912797 hasRelatedWork W2056132396 @default.
• W3176912797 hasRelatedWork W2105175916 @default.
• W3176912797 hasRelatedWork W2168053185 @default.
• W3176912797 hasRelatedWork W2969482432 @default.
• W3176912797 hasRelatedWork W2982647896 @default.
• W3176912797 hasRelatedWork W3013404192 @default.
• W3176912797 hasRelatedWork W3035929250 @default.
• W3176912797 hasRelatedWork W3044601235 @default.
• W3176912797 hasRelatedWork W4255291254 @default.
• W3176912797 hasVolume "28" @default.
• W3176912797 isParatext "false" @default.
• W3176912797 isRetracted "false" @default.

• next